Palatin Technologies, Inc.
PTN
Rank in Stocks
#27956
Palatin Technologies, Inc., a biopharmaceutical company, develops... Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Share Price
$7.23
Last synced: 2026-11-09
Market Cap
$12.88M
Change (1 day)
15.31%
Change (1 year)
-15.24%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Palatin Technologies, Inc. (PTN)
Category
Healthcare
Operating Margin for Palatin Technologies, Inc. (PTN)
Operating Margin as of November 2026 TTM: -65.74%
According to Palatin Technologies, Inc.'s latest financial reports, its current operating margin (TTM) is -65.74%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Palatin Technologies, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -65.74% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -501.02% | -25.08% |
| 2023 | -668.75% | -73.16% |
| 2022 | -2,491.63% | -114.08% |
| 2021 | 17,701.29% | -188.47% |
| 2020 | -20,007.61% | -33,851.03% |
| 2019 | 59.28% | 53.50% |
| 2018 | 38.62% | -263.44% |
| 2017 | -23.63% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -133.47% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -150,421.39% | 490.43% |
| 2012 | -25,476.54% | 2,653.12% |
| 2011 | -925.37% | 4,252.63% |
| 2010 | -21.26% | -66.95% |
| 2009 | -64.32% | -55.59% |
| 2008 | -144.84% | -29.99% |
| 2007 | -206.87% | 34.17% |
| 2006 | -154.19% | 79.65% |
| 2005 | -85.83% | -92.57% |
| 2004 | -1,155.76% | -30.22% |
| 2003 | -1,656.34% | -72.33% |
| 2002 | -5,985.25% | 843.27% |
| 2001 | -634.52% | 279.32% |
| 2000 | -167.28% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.59% |
US
|
|
| -149.01% | -97.73% |
US
|
|
| 25.57% | -100.39% |
AU
|
|
| 31.23% | -100.48% |
BE
|
|
| 29.35% | -100.45% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Palatin Technologies, Inc.'s operating margin
What is Palatin Technologies, Inc.'s operating margin?
Palatin Technologies, Inc.'s operating margin is -65.74%, as of Nov 2026.
What was Palatin Technologies, Inc.'s operating margin in 2025?
In 2025, Palatin Technologies, Inc.'s operating margin was 0.00%, compared with -501.02% in 2024.
How has Palatin Technologies, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Palatin Technologies, Inc.'s operating margin was highest in 2021 (17,701.29%) and lowest in 2020 (-20,007.61%).
How does Palatin Technologies, Inc.'s operating margin compare with similar companies?
Palatin Technologies, Inc.'s operating margin (-65.74%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.